What are the recommendations for aspirin use in primary prevention of cardiovascular disease?
The European Association for Cardiovascular Prevention & Rehabilitation (EACPR) recommends that aspirin may be used for primary prevention in individuals at moderate risk of cardiovascular disease, as suggested by the ARRIVE trial. The American Diabetes Association, the American Heart Association and the American College of Cardiology Foundation have all issued position statements recommending aspirin for primary prevention of cardiovascular disease in people with diabetes. The European Society of Cardiology has also issued a position paper recommending aspirin for primary prevention of atherosclerotic cardiovascular disease.